Public Invited to NSCI Open House

OH_banner_2016

We invite the public to an Open House and cocktail reception at the Neural Stem Cell Institute on Thursday, May 19, 2016 from 4:30 – 7pm.  

Please join this exciting informational event and learn about the impact of stem cell research on medicine and health care.  Speakers include Dr. Sally Temple and Dr. Jeffrey Stern. Tour our state of the art laboratories and view actual stem cells.   

The Neural Stem Cell Institute (NSCI) is dedicated to developing regenerative stem cell therapies for various diseases of the central nervous system (CNS): the brain, spinal cord and retina. Led by MacArthur Award winner Dr. Sally Temple who helped discover and define nervous system stem cells, NSCI is the first independent, non-profit stem cell research institute in the USA.

1 Discovery Drive, Rensselaer, NY  12144 – (518) 694-8188

RSVP not required. Business casual

WaferGen Bio-systems Announces Placement of ICELL8TM Single-Cell System at Neural Stem Cell Institute

ICELL8™ Single-Cell System to Enable Innovative Stem Cell and Regenerative Medicine Research

FREMONT, California, March 3, 2016 — WaferGen Bio-systems (NASDAQ: WGBS), a life sciences tools company focused on developing and commercializing technology platforms for genomics solutions,announced today that the Neural Stem Cell Institute (NSCI), a not-for-profit organization that specializes in translational therapeutic stem cell research for diseases of the nervous system, located in Rensselaer,New York, recently selected the ICELL8™ Single-Cell System to conduct innovative stem cell research,with the goal of developing novel therapies for diseases of the brain and spinal cord.

“The ICELL8™ system will enable greater throughput and analysis of heterogeneous cells of different sizes,” said Dr. Sally Temple, a leader in the field of neural stem cells and the Scientific Director of theNSCI. “With the added ability to image and choose specific cells, we will be able to conduct experiments with greater confidence and interrogate specific stem cell subtypes quickly and effectively.”

“We are pleased that the NSCI, a leader in developing regenerative stem cell discoveries and therapies,has selected the ICELL8™ system to advance their single cell genomics research in diseases of the nervous system,” said Rolland Carlson, Ph.D., President and Chief Executive Officer of WaferGen Bio-systems. “The ICELL8™ Single-Cell system’s ability to isolate cells from tissues that have previously been inaccessible to single-cell genomics will enable innovative research for both stem cell and neuroscience researchers in the future.”

The ICELL8™ Single-Cell System is a revolutionary platform with the ability to isolate thousands of single cells and process specific cells of interest for downstream analysis using Next Generation Sequencing. The system includes an imaging station and CellSelect™ software for imaging and automatic selection of single cells for downstream processing. Recently, WaferGen’s Early-Access partners presented compelling results related to their use of the system at the Advances in Genome Biology and Technology 2016 General Meeting, including data from studies with neural cells.

About Neural Stem Cell Institute

The Neural Stem Cell Institute (NSCI) is a non-profit 501 (c)(3) organization and the first independent,neural stem cell research institute in the United States. Headquartered at the East Campus of the University at Albany in Rensselaer, NY. NSCI is a unique organization that produces leading stem cell research to develop new therapies for diseases of the central nervous system such as Alzheimer’s Disease, Parkinson’s Disease and Age-related Macular Degeneration. NSCI aims to harness the power of stem cells to ease suffering caused by injury and disease of the brain, spinal cord and retina. NSCI has over 30 individuals focused on finding new ways to promote nervous system repair and has published numerous articles on groundbreaking stem cell discoveries and their implications for neural disease cures.

About WaferGen

WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The single cell analysis platform is a revolutionary system which can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing (NGS). The SmartChip platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel single-plex PCR for one-step target enrichment and library preparation for clinical NGS. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical, and clinical laboratory industries.

For additional information, please see http://www.wafergen.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms.  Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage, our expectations regarding our development of future products including single cell analysis technologies and our expectations concerning our competitive position and business strategy.  Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward- looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward- looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

WAFERGEN CONTACTS

LifeSci Advisors, LLC

Brian Ritchie

BRitchie@LifeSciAdvisors.com

WaferGen Bio-systems, Inc.

Rollie Carlson

Rollie.Carlson@wafergen.com

Stem Cell Battles: Proposition 71 and Beyond: How Ordinary People Can Fight Back Against the Crushing Burden of Chronic Disease

Now available on Amazon, Don Reed’s book, Stem Cell Battles: Proposition 71 and Beyond: How Ordinary People Can Fight Back Against the Crushing Burden of Chronic Disease. Mr.Reed sponsored California’s Roman Reed Spinal Cord Injury Research Act of 1999.  Named after his paralyzed son Roman, “Roman’s Law” provided and attracted millions of dollars for stem cell research. Reed also organized groundbreaking supportive legislation. He says in the Huffington Post:

“It’s 2016, I am 70 years old, and just published a book on stem cell research…with a posthumous foreword by Christopher Reeve.

For me as the father of a paralyzed young man, Roman Reed, I am eternally grateful to Paul Richter, the policeman who was shot in the line of duty, but then went on to inspire a paralysis research program — and Dr. Sally Temple, co-founder of the Neural Stem Cell Institute; and Brooke Ellison, a paralyzed woman who inspired Christopher Reeve’s last movie, The Brooke Ellison Story — and groundbreaking scientist Loren Studer, fighting for a cure of Alzheimers’ and ALS. Too many to even try to name them all!”

Read more about Don Reed and his book here.

 

CurePSP Panel: The Theory of Everything

Temple_NSCI

Dr. Sally Temple

NSCI’s Scientific Director was invited by Cure PSP to join a group of eminent investigators moderated by Pulitzer Prize-winning author Jonathan Weiner in a discussion of the latest developments in neurodegeneration research. CurePSP is the leading nonprofit advocacy organization focused on prime of life neurodegenerative diseases – a spectrum of fatal brain disorders that often strike during a person’s most productive and rewarding years. Since it was founded in 1990, CurePSP has funded more than 160 research studies primarily in supranuclear palsy (PSP) and the related disease corticobasal degeneration (CBD) and is the leading source of information and support for patients and their families, other caregivers, researchers, and doctors and other healthcare professionals.

Listen to entire discussion here.

Dr. Kristen Zuloaga Receives American Heart Association Award for Study of Link Between Pre-Diabetes and Vascular Cognitive Impairment

Zuloaga

Dr. Kristen Zuloaga

NSCI’s research scientist, Dr. Kristen Zuloaga has been awarded a four year grant from the American Heart Association for her study of the relationship between pre-diabetes and vascular cognitive impairment, which is the second most common cause of dementia. Dr. Zuloaga is also analyzing the potential results for each sex. She is looking at aromatase expression and how this affects cognition in male vs. female. Aromatase inhibitors are often used for treating breast cancer. Understanding this relationship could have important clinical implications. See full project summary below:

Vascular cognitive impairment (VCI) is the second most common cause of dementia. Diabetes increases VCI risk,an effect that has largely been attributed to vascular dysfunction caused by diabetes. Prediabetes, impaired glucose tolerance in the absence of hyperglycemia, is increasingly recognized as its own disease state and is also associated with endothelial dysfunction. Our preliminary data show that prediabetes, modeled by high fat (HF) diet in mice, causes cerebral hypoperfusion and cognitive deficits, suggesting that prediabetes may also increase risk of VCI. There is a sex difference in cardiovascular disease risk, as pre-menopausal women are normally at decreased risk compared to age-matched men. However, this sex differences is reversed in diabetes, suggesting that endogenous sex steroid pathways may be altered in these women. In both sexes, a major source of estrogen is local synthesis of estradiol by the enzyme aromatase in a variety of cells, including endothelial cells. We have shown that inhibition of aromatase drastically impairs endothelial function in female mice, but not male mice. Aromatase inhibition also impairs learning and memory, with effects being more pronounced in females. In addition, brain aromatase levels have been shown to be drastically decreased in women with Alzheimers disease. However, the role of aromatase in VCI and the mechanism by which prediabetes can alter its expression has yet to be explored. We will test the hypothesis that in a mouse model of VCI, HFD/prediabetes will cause increased cerebral hypoperfusion and cognitive deficits in females compared to males due to decreased endothelial aromatase expression. We will utilize unilateral common carotid artery occlusion (UCCAO) to model VCI. In aim 1, we will determine there are sex differences in the effects of HF diet on cerebral perfusion and cognitive deficits following UCCAO. In aim 2, we will determine if HF diet-induced alterations in cerebrovascular vasodilator production are due to decreases in endothelial aromatase. Finally, in aim 3, we will determine if endothelial aromatase deficiency causes cerebral hypoperfusion and increase cognitive deficits following UCCAO in a sex-specific manner and if aromatase overexpression can rescue endothelial vasodilator production in HF diet mice. This project has important clinical implications since aromatase inhibitors, which are a common therapeutic for breast cancer, have been linked to impaired cognition in women.

Kristen obtained her PhD in biomedical sciences in 2011.  Her graduate work focused on the effects of sex hormones on cerebrovascular inflammation. Next, as a postdoc at Oregon Health and Science University under the mentorship of Dr. Nabil Alkayed, she examined how sex differences in cerebrovascular function influence stroke outcome and contribute to vascular dementia.